Taysha Gene Therapies, Inc. (TSHA) compared with its closest peers (ADMA, VCEL, RXRX, MAZE, VIR). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.26B | 13.7 |
| Vericel Corporation (VCEL) | $2.15B | 112.5 |
| Recursion Pharmaceuticals, Inc. (RXRX) | $1.77B | -2.8 |
| Maze Therapeutics, Inc. (MAZE) | $1.61B | -13.6 |
| Vir Biotechnology, Inc. (VIR) | $1.55B | -1.9 |
| Inhibrx Biosciences, Inc. (INBX) | $1.46B | -8.7 |
| Novavax, Inc. (NVAX) | $1.39B | 2.6 |
| Cullinan Therapeutics, Inc. (CGEM) | $1.38B | — |
| Replimune Group, Inc. (REPL) | $1.32B | -2.3 |
| Monte Rosa Therapeutics, Inc. (GLUE) | $1.26B | -34.1 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
TSHA overview · TSHA earnings · TSHA financials · TSHA KPIs · TSHA investor relations · TSHA ownership · TSHA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.